Inotek Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference.

BEVERLY, Mass. -- Inotek Pharmaceuticals Corporation today announced that Dr. Andrew Salzman, President and Chief Executive Officer of Inotek Pharmaceuticals, will present at the 25th Annual JP Morgan Healthcare Conference in San Francisco at 2:30 p.m. local time (5:30 p.m. eastern time) on Tuesday, January 9, 2007.

About Inotek Pharmaceuticals

Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a Phase 2, drug-development company with a deep pipeline of small molecule compounds targeting the key biological processes involved in cell survival and tissue injury. Inotek was founded in 1996 and currently has 140 employees, located in its corporate headquarters and main research laboratories in Beverly, Massachusetts and its clinical operations and GMP production facilities in Israel. Inotek has developed integrated capabilities from early discovery through Phase 2 clinical development.

Inotek's three platform programs have resulted in 7 novel molecules in various stages of preclinical and clinical development which target: 1) PARP, a fundamental DNA repair and inflammation target; 2) free radicals & oxidants; and 3) purines with a specific focus on adenosine receptors and inosine. The Company's lead Phase 2 clinical program is focused on the development of potent oral and i.v. inhibitors of the nuclear enzyme poly (ADP-ribose) polymerase or PARP. In 2006, the Company executed a $600+ million global partnership with Genentech relating to Inotek's PARP inhibitor program in cancer. Inotek's other clinical stage product, an oral anti-inflammatory compound, is being developed as a treatment for inflammatory bowel disease and other inflammatory conditions. Three additional clinical candidates are expected to enter Phase 1 clinical trials in 2007.